Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.44 |
| ▸ | HTR3A | P46098 | 6/20 | 0.41 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13152403 | 0.89 | ALDH1A1 (0.35) | HRH3KCNH2ADRA1A | |
| SCHEMBL13152137 | 0.88 | HRH3 (0.42) | HRH3KCNH2ADRA1AHTR3AHRH2 | |
| SCHEMBL10096382 | 0.88 | HRH3 (0.46) | HRH3KCNH2ADRA1AHTR3AHRH2 | |
| SCHEMBL13152262 | 0.87 | ALDH1A1 (0.37) | — | |
| SCHEMBL13151973 | 0.85 | HRH3 (0.43) | HRH3KCNH2ADRA1AHTR3A | |
| SCHEMBL10097311 | 0.84 | HSD17B10 (0.47) | — | |
| SCHEMBL10249762 | 0.84 | HRH3 (0.49) | HRH3KCNH2ADRA1AHTR3AHRH1 | |
| SCHEMBL12950080 | 0.84 | ALDH1A1 (0.41) | HRH3KCNH2HRH2HRH1 | |
| SCHEMBL12334861 | 0.80 | ESR1 (0.39) | HRH3KCNH2ADRA1A | |
| SCHEMBL10249587 | 0.79 | HRH3 (0.46) | HRH3KCNH2ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | PTC THERAPEUTICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2010118009-A1 | HCV INHIBITOR AND THERAPEUTIC AGENT COMBINATIONS | PTC THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2007084435-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | HAVCR2, SERPINB1, ENPEP | HRH3 3196/4885KCNH2 4859/4885ADRA1A 3920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.